

Aurinia Pharmaceuticals shares are trading lower Thursday afternoon after the lupus-focused drugmaker posts a blowout fourth quarter and raises expectations for...
You can purchase shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) through any online brokerage.
Other companies in Aurinia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Aurinia Pharmaceuticals has a consensus price target of $15.86.
The stock price for Aurinia Pharmaceuticals (NASDAQ: AUPH) is $16.98 last updated October 22, 2026 at 5:27 PM EDT.
There are no upcoming dividends for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for...